
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
Comparing outcomes between adult patients living with generalized myasthenia gravis (gMG) who received inebilizumab (Uplizna; Amngen) and those who received placebo, the humanized monoclonal antibody produced superior efficacy and safety results through …